drugset / Trial / NCT06504186
The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation
NaSingle-groupOpen-labelPrevention
Summary
To explore the efficacy and safety ofblinatumomab± TKI in B-ALL patients aged ≥ 14 years with NGS-MRD relapse (sensitivity: 10-6) after auto/allo HSCT, and to observe the disease-free survival (DFS), recurrence rate and toxicity after transplantation.
Timeline
- Start
- 2024-07
- Primary completion
- 2026-06
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | 28 ug | — |
| Subject | Blinatumomab | Monoclonal antibody | 15 mg/m2 | — |
Indications
No indication recorded.